在寻找脊柱肌肉缩的疾病修饰者
Daria Chudakova1, Ludmila Kuzenkova1, Andrey Fisenko1
1National Medical Research Center of Children's Health of the Ministry of Health of the Russian Federation, 119991 Moscow, Russia.
International journal of molecular sciences
|October 26, 2024
概括
脊柱肌缩 (SMA) 是一种影响运动神经元的遗传疾病. 疾病修饰剂显著影响SMA的SMA.
科学领域:
- 遗传学 是一个遗传学.
- 神经退行性疾病 神经退行性疾病
- 分子生物学分子生物学
背景情况:
- 脊椎肌肉缩 (SMA) 是一种遗传性,自体逆向性神经退行性疾病.
- 它是由生存运动神经元1 (SMN1) 基因的突变引起的,是婴儿死亡的主要原因.
- SMA表现出临床严重性的范围,受遗传和表观遗传因素的影响,称为疾病修饰剂 (DMs).
研究的目的:
- 提供SMA遗传学,病理生物学及其真正的疾病修饰剂的概述.
- 描述新兴的DM,识别方法及其潜在的作用机制.
- 探索SMA表型变化背后的分子机制.
主要方法:
- 这篇叙事综述综合了有关SMA遗传学和疾病修饰剂的现有文献.
- 它讨论了用于识别DM的新方法和工具.
- 它检查了DMs对SMA疾病严重性的影响,并提出了分子机制.
主要成果:
- 已确定的遗传和表观遗传因素 (DMs) 调节SMA的临床严重程度,甚至在具有相同SMN1突变的个体中解释表型变异性.
- 描述了新出现的DM及其路径,强调它们在疾病进展中的作用.
- 提出了对SMA表型多样性的贡献的新型分子机制.
结论:
- 了解DMs对于增强目前的SMA疗法,以SMN蛋白恢复为重点,至关重要.
- DMs代表了SMA潜在的新型治疗点和预后生物标志物.
- 对DM的进一步研究可以阐明SMA可变临床表现的分子基础.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Satellite Stem Cells and Muscular Dystrophy
1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K
Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486
Disorders of the Skeletal Muscle
896
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
896
Classification of Skeletal Muscle Relaxants
2.4K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.4K
Myasthenia Gravis: Diagnostic Tests
673
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
673


